n CME : Your SA Journal of CPD - Lapatinib (Tykerb) : more about... breast cancer




The most exciting aspect is the fact that lapatinib is really the first of many targeted intracellular agents in breast cancer and already numerous other tyrosine kinase inhibitors aimed at many aspects of the cytokine cascade are in clinical development and being studied in breast cancer. There is a long way to go to a full understanding, but the era of truly targeted anti-cancer therapy has dawned.


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error